Categories
Biocon Limited — Updates, 07-05-2026: Press Release
07-05-2026 · 11:37 pm
Biocon posted robust FY26 results with Net Profit soaring 323%@ to Rs 436 Cr. Total Income reached Rs 17,270 Cr (+14%@). Growth driven by Biosimilars & Generics performance, including US FDA approval for generic Liraglutide. A Re 0.50/share final dividend is proposed.
No comments yet. Be the first to comment!